查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836734

無針給藥裝置市場按產品類型、藥物類型、給藥途徑、應用、最終用戶和分銷管道分類 - 全球預測，2025-2032

Needle Free Drug Delivery Device Market by Product Type, Drug Type, Administration Route, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，無針給藥裝置市場規模將成長至 440.2 億美元，複合年成長率為 15.70%。

主要市場統計數據
基準年2024年 137億美元
預計2025年 158.5億美元
預測年份：2032年 440.2億美元
複合年成長率（%） 15.70%

關於無針輸送創新的權威概述，包括臨床益處、病患採用以及影響發展的策略重點

隨著醫療保健系統、患者和技術創新者齊心協力，致力於減少治療障礙的解決方案，藥物管理格局正在迅速演變。無針給藥裝置解決了各種臨床和操作挑戰：減少針頭相關的焦慮和臨床併發症，簡化社區和家庭給藥，並實現生物製藥和疫苗的新型給藥方法。這些醫療設備對那些重視依從性、安全性和擴大疫苗宣傳活動的相關人員越來越有吸引力。

早期臨床證據和現實世界試點計畫已證明多個平台具有良好的免疫抗原性和藥物動力學特性，而人體因素研究則強調，與傳統注射器相比，該平台的患者接受度更高。此外，材料科學、微加工和精密工程的融合正在加速設備外形規格的迭代，從高速噴射注射器到皮膚整合微陣列貼片。因此，開發人員正在重新思考配方策略、低溫運輸要求和包裝，以充分利用無針方法提供的獨特給藥途徑。

因此，付款人和醫療系統正在評估其所有益處，包括減少尖銳廢棄物和臨床人員需求。同時，投資者和企業負責人在考慮商業性部署時必須考慮監管途徑、報銷複雜性和生產規模。本文將作為深入分析的引言，涵蓋技術變革、政策影響、細分市場動態、區域前景和可操作建議。

技術、臨床、監管和經濟的變化正在重塑無針注射的格局和商業化路徑

在技​​術、臨床和政策力量融合的推動下，無針注射的格局已進入變革期。在技​​術方面，微陣列製造和精密氣體或彈簧驅動噴射系統的進步顯著提高了給藥精度、皮膚穿透的一致性以及使用者人體工學。這些工程改進，加上製藥業在將生技藥品和疫苗應用於非侵入性途徑方面的進步，正在擴大無針治療的治療應用範圍。

臨床實踐日益將醫療照護分散化，更傾向於適用於門診手術中心、醫生診所、家庭醫療機構以及藥房疫苗接種計畫的治療方法。因此，開發人員優先考慮易用性、簡化培訓和設備安全性，以支援非專業管理。法律規範也不斷發展，以適應新的管理機制，各機構更加重視人為因素數據和比較安全證據。這種監管重點加速了設備的改進，同時也提高了在人群中表現出一致性能的綜合臨床項目的標準。

出於經濟原因，供應鏈的彈性和擴充性至關重要。製造商正在探索垂直整合生產和關鍵零件的策略性採購，以降低風險。同時，付款人和醫療系統也越來越重視能夠縮短給藥時間、降低廢棄物管理成本和提高依從性的證據。總而言之，這些轉型正在重塑產品藍圖和商業策略，以優先考慮互通性、以患者為中心的設計和切實可行的部署路徑。

分析2025年關稅政策轉變如何促使無針醫療設備生態系統的供應鏈重組、採購多樣化與生產策略調整。

關稅和貿易行動等政策調整對複雜的醫療設備供應鏈產生了切實的影響，而美國在2025年左右頒布或宣布的關稅，也為無針輸送系統的製造商、經銷商和採購商帶來了新的考量。對零件、次組件和特殊金屬徵收關稅可能會增加醫療設備製造商的投入成本，促使他們重新評估供應商合約和採購區域。為此，一些公司加快了供應商多元化舉措，並增加了庫存緩衝，以保障生產的連續性。

此外，關稅可能會改變組裝和最終製造地點的計算。一些公司已經評估了近岸外包或回流策略，以最大限度地降低關稅的影響並縮短前置作業時間，但此類措施需要資本投資和謹慎的監管協調。同時，經銷商和醫療保健提供者也考慮了採購契約，以了解轉嫁定價動態，並保持其資本和消耗品採購預算的可預測性。

重要的是，關稅也與更廣泛的貿易關係和監管協調工作息息相關。依賴跨境臨床供應鏈的製造商必須避免海關的複雜性和潛在的延誤，因為這些因素會影響產品發布和現場試驗。因此，各公司已投入大量資金進行情境規劃和供應商網路壓力測試，以確保其實施時間表和臨床項目在政策波動的情況下仍保持穩健。簡而言之，2025 年的關稅趨勢強化了對供應鏈敏捷性、區域製造策略以及支持患者不間斷用藥的合約保障措施的關注。

綜合細分情報，將產品架構、藥品組合、給藥途徑、應用、最終用戶和分銷管道與戰略選擇聯繫起來

精細細分揭示了不同的技術路徑和臨床用例​​，為產品和市場策略提供參考。根據產品類型，該領域涵蓋噴射注射器和微陣列貼片平台。噴射注射器架構進一步定義了氣動和彈簧驅動機制的選擇，而微陣列貼片的開發則涵蓋可溶解、中空和固體微陣列方法。這些工程差異會影響設備成本結構、無菌考量和患者互動模式，而每種因素都會影響其在不同醫療環境中的採用。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 透過藍牙連接將即時血糖監測與穿戴式無針胰島素輸送裝置結合
  • 高壓噴射注射器的出現，用於大規模疫苗宣傳活動，以減少資源匱乏地區對低溫運輸的依賴
  • 生技公司與設備製造商合作開發透過無針電穿孔系統給藥的質體DNA 疫苗
  • 透過在居家照護環境中引入彈簧式無針注射器來注射生物製藥，提高患者的依從性並減少浪費。
  • 經鼻吸入型疫苗遞送平台獲監管部門核准，可標靶治療呼吸道病原體並提高粘膜免疫力

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 無針給藥裝置市場（依產品類型）

  • 噴射注射器
    • 瓦斯動力
    • 彈簧底座
  • 微陣列貼片
    • 可溶解微陣列
    • 中空微陣列
    • 固體微陣列

9. 無針給藥裝置市場（依藥物類型）

  • 胰島素
    • 基礎胰島素
      • 中效胰島素
      • 長效胰島素
    • Bolus胰島素
      • 速效胰島素
      • 短效胰島素
  • 疫苗
    • 2019冠狀病毒病疫苗
      • mRNA疫苗
      • 病毒載體疫苗
    • 流感疫苗
      • H5N1流感
      • 季節性流感

10. 無針給藥裝置市場（依給藥途徑）

  • 皮內
  • 肌肉注射
  • 皮下

第11章無針給藥裝置市場（依應用）

  • 皮膚科
  • 糖尿病管理
  • 免疫
  • 疼痛管理

12. 無針給藥裝置市場（依最終用戶）

  • 門診手術中心
  • 診所
  • 家庭環境
  • 醫院

13. 無針給藥裝置市場（依分銷管道）

  • 離線
  • 線上

14. 無針給藥裝置市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 無針給藥裝置市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 無針給藥裝置市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • PharmaJet, Inc.
    • Antares Pharma, Inc.
    • West Pharmaceutical Services, Inc.
    • Nitto Denko Corporation
    • Haselmeier GmbH
    • Nemera SA
    • Kindeva Drug Delivery LLC
    • Vaxxas Pty Ltd
    • Bioject Medical Technologies, Inc.
    • Zosano Pharma Corporation
Product Code: MRR-036C5CF3B48C

The Needle Free Drug Delivery Device Market is projected to grow by USD 44.02 billion at a CAGR of 15.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.70 billion
Estimated Year [2025] USD 15.85 billion
Forecast Year [2032] USD 44.02 billion
CAGR (%) 15.70%

An authoritative overview of needle-free delivery innovations that frame clinical benefits, patient adoption, and the strategic priorities shaping development

The landscape of drug administration is rapidly evolving as healthcare systems, patients, and technology innovators converge on solutions that reduce barriers to care. Needle-free drug delivery devices address a spectrum of clinical and operational pain points: they reduce the anxiety and clinical complications associated with needle use, simplify administration in community and home settings, and enable new modalities for biologic and vaccine delivery. These devices are increasingly attractive to stakeholders who prioritize adherence, safety, and scaled immunization campaigns.

Early clinical evidence and real-world pilot programs indicate promising immunogenicity and pharmacokinetic profiles for several platforms, while human factors research underscores higher patient acceptance relative to traditional syringes. Moreover, the convergence of materials science, microfabrication, and precision engineering has accelerated iterations of device form factors, from high-velocity jet injectors to skin-integrated microarray patches. As a result, developers are rethinking formulation strategies, cold-chain requirements, and packaging to leverage the unique administration routes offered by needle-free approaches.

Consequently, payers and health systems are evaluating the totality of benefits, including potential reductions in sharps waste and clinical staffing demands. In turn, investors and corporate strategists must weigh regulatory pathways, reimbursement complexities, and manufacturing scale when considering commercial deployment. This introductory synthesis sets the stage for a deeper analysis of technology shifts, policy impacts, segmentation dynamics, regional outlooks, and actionable recommendations that follow.

Exploring the convergent technological, clinical, regulatory, and economic shifts reshaping the needle-free delivery landscape and commercialization pathways

The needle-free delivery landscape has entered a period of transformative shifts driven by converging technological, clinical, and policy forces. On the technology front, advances in microarray fabrication and high-precision gas- or spring-driven jet systems have materially improved dosing accuracy, skin penetration consistency, and user ergonomics. These engineering improvements are coupled with formulation science that adapts biologics and vaccines to non-invasive routes, thereby widening the therapeutic applicability of needle-free approaches.

Clinically, there is a shift toward decentralization of care that favors modalities suitable for ambulatory surgical centers, clinics, home care settings, and pharmacy-based immunization programs. As a result, developers are prioritizing usability, simplified training, and device safety features to support non-specialist administration. Regulatory frameworks are simultaneously evolving to accommodate novel delivery mechanisms, with agencies emphasizing human factors data and comparative safety evidence. This regulatory attention accelerates device refinement but also raises the bar for comprehensive clinical programs that demonstrate consistent performance across populations.

Economically, supply chain resilience and scalability have become predominant considerations. Manufacturers are exploring vertically integrated production and strategic sourcing of critical components to mitigate risk. Meanwhile, payers and health systems are increasingly interested in evidence that demonstrates reductions in administration time, waste management costs, and improved adherence. Taken together, these transformative shifts are reshaping product roadmaps and commercial strategies in ways that prioritize interoperability, patient-centric design, and pragmatic implementation pathways.

Analyzing how 2025 tariff policy shifts prompted supply chain reconfiguration, sourcing diversification, and production strategy adjustments across needle-free device ecosystems

Policy adjustments such as tariffs and trade measures exert tangible influence over complex medical device supply chains, and the United States tariff actions enacted or announced around 2025 introduced new considerations for manufacturers, distributors, and purchasers of needle-free delivery systems. Tariffs on components, subassemblies, or specialty metals can increase input costs for device makers, prompting reassessments of supplier contracts and sourcing geographies. In response, several firms accelerated supplier diversification initiatives and increased inventory buffers to protect production continuity.

Moreover, tariffs can change the calculus around where to locate assembly and final manufacturing. Some organizations evaluated nearshoring or reshoring strategies to minimize tariff exposure and reduce lead times, although such moves require capital investment and careful regulatory alignment. In parallel, distributors and healthcare providers examined procurement agreements to understand pass-through pricing dynamics and to preserve budget predictability for capital and consumable purchases.

Importantly, tariffs also intersect with broader trade relationships and regulatory harmonization efforts. Manufacturers that rely on cross-border clinical supply chains must navigate customs clearance complexities and potential delays that affect product launches and field trials. Consequently, firms invested more heavily in scenario planning and stress-testing their vendor networks to ensure that implementation timelines and clinical programs remain robust despite policy volatility. In short, tariff dynamics in 2025 intensified focus on supply chain agility, regional manufacturing strategies, and contractual safeguards that support uninterrupted patient access.

Comprehensive segmentation intelligence tying product architectures, drug portfolios, administration routes, applications, end users, and distribution channels to strategic choices

A granular view of segmentation reveals distinct technology pathways and clinical use cases that inform product and go-to-market strategies. Based on Product Type, the domain encompasses Jet Injector and Microarray Patch platforms; Jet Injector architectures are further defined by choices between Gas Powered and Spring Based mechanisms, while Microarray Patch developments span Dissolvable Microarray, Hollow Microarray, and Solid Microarray approaches. These engineering distinctions influence device cost structure, sterility considerations, and patient interaction models, each of which bears on adoption in different care settings.

Based on Drug Type, delivery systems are being optimized for Insulin and Vaccines. The insulin portfolio divides into Basal Insulin and Bolus Insulin, where Basal options break down further into Intermediate Acting Insulin and Long Acting Insulin and Bolus options include Rapid Acting Insulin and Short Acting Insulin. Vaccines are characterized across Covid-19 Vaccine and Influenza Vaccine categories, with Covid-19 modalities including Mrna Vaccine and Viral Vector Vaccine and Influenza formulations encompassing H5N1 Influenza and Seasonal Influenza. These drug-type distinctions inform formulation stability, dosing volume constraints, and regulatory evidence requirements, shaping which platforms are prioritized for clinical development.

Based on Administration Route, strategies differ among Intradermal, Intramuscular, and Subcutaneous delivery, each route affecting immunogenicity, absorption kinetics, and tolerability profiles. Based on Application, clinical focus areas include Dermatology, Diabetes Management, Immunization, and Pain Management, and each therapeutic area presents unique user needs and reimbursement considerations. Based on End User, adoption scenarios unfold across Ambulatory Surgical Centers, Clinics, Home Care Settings, and Hospitals, which dictate training burdens and procurement channels. Finally, Based on Distribution Channel, reach and logistical models vary between Offline and Online pathways, influencing how manufacturers structure fulfillment, customer education, and after-sales support. Integrating these segmentation layers yields actionable insights for prioritizing R&D pipelines, clinical programs, and commercialization sequences.

Discerning how regional healthcare structures, regulatory priorities, and manufacturing capabilities in the Americas, EMEA, and Asia-Pacific shape deployment and adoption

Regional dynamics create differentiated opportunities and constraints that manufacturers and payers must navigate carefully. In the Americas, pathways to adoption often emphasize commercialization speed, payer engagement, and integration into primary care and pharmacy networks. Studies in the region frequently highlight convenience and adherence improvements as key drivers for uptake, while supply chain logistics and domestic manufacturing footprints influence procurement decisions.

In Europe, Middle East & Africa, regulatory alignment, public health priorities, and diversified healthcare delivery models shape the deployment of needle-free devices. Payers and national immunization programs in some jurisdictions prioritize evidence of cost-effectiveness and programmatic fit, while in other parts of the region, infrastructure limitations create opportunities for simplified, robust devices that lower cold-chain dependency and enable mass immunization campaigns.

In Asia-Pacific, high population density, strong contract manufacturing capabilities, and proactive public health initiatives drive interest in scalable delivery technologies. Rapid urbanization and expanding pharmacy and clinic networks present multiple channels for adoption, while regional manufacturers often provide competitive production capacity that facilitates localized supply. Across regions, strategic partnerships, regulatory strategy, and alignment with public health objectives are decisive factors that influence clinical rollout and commercial performance.

Examining platform strategies, partnership dynamics, regulatory engagement, and supply chain investments that define how leading companies scale needle-free solutions

Leading organizations across device engineering, pharmaceutical development, and contract manufacturing are advancing differentiated strategies that accelerate clinical validation and commercial readiness. Some innovators concentrate on platform modularity to accommodate a range of drug types and administration routes, enabling a single device architecture to support both vaccine campaigns and chronic disease therapies. Others prioritize single-use simplicity and supply chain robustness to support mass immunization or home administration scenarios.

Partnership models have become central to scaling capabilities; device developers frequently collaborate with formulation scientists, CMOs, and specialty packaging providers to align stability, sterility, and dosage accuracy. Such collaborations speed technical de-risking and create integrated value propositions for healthcare systems. In addition, firms are investing in post-market surveillance infrastructure and human factors research to gather real-world performance data that supports iterative device improvements and payer conversations.

Manufacturers with established regulatory expertise are leveraging early engagement with agencies to clarify evidence expectations, while those with broader commercial footprints focus on distribution partnerships to expedite market access. Strategic investors and corporate development teams are likewise active, supporting consolidation and capability acquisition in areas such as microfabrication, bioresorbable materials, and cold-chain logistics. Collectively, these corporate moves shape the competitive structure and the innovation trajectory of the needle-free delivery sector.

Actionable strategies for leaders to align product modularity, supply chain resilience, regulatory engagement, real-world evidence, and partnership ecosystems to accelerate adoption

Industry leaders should pursue an integrated set of actions that align technical development with pragmatic commercial execution. First, prioritize modular device designs that can accommodate multiple drug types and administration routes to maximize platform utility and to reduce per-program development timelines. Concurrently, invest in formulation and stability programs that anticipate the unique demands of intradermal, intramuscular, and subcutaneous delivery to minimize downstream technical barriers.

Second, strengthen supply chain resilience through supplier diversification, strategic inventory policies, and consideration of regional manufacturing footprints. This reduces exposure to policy-driven tariffs and customs complexities while supporting rapid scale-up. Third, engage regulators early and iteratively to align clinical programs with human factors and comparative safety evidence expectations, thereby streamlining approval pathways. Fourth, develop robust real-world evidence and health economic frameworks that communicate the operational and patient-centric advantages of needle-free solutions to payers and health systems.

Finally, cultivate partnerships across contract manufacturers, specialty formulators, and distribution channels to accelerate time-to-clinic and time-to-patient. Tailor go-to-market approaches for distinct end users, including hospitals, clinics, ambulatory surgical centers, and home care settings, and leverage online and offline distribution models to optimize reach. By executing these actions in combination, organizations can reduce technical and commercial risk while positioning their solutions for sustainable adoption.

Methodology integrating primary stakeholder interviews, regulatory and technical dossier review, comparative device analysis, and supply chain evaluation to validate findings

This research synthesis is based on a rigorous, mixed-methods approach that integrates primary interviews, regulatory filings, device and formulation literature, and supply chain analyses. Primary data inputs included structured interviews with clinical investigators, device engineers, formulation scientists, procurement leaders, and end users across hospitals, clinics, ambulatory centers, and home-care programs to capture diverse perspectives on usability, performance, and adoption barriers. Secondary inputs encompassed peer-reviewed journals, regulatory guidance documents, technical white papers, and public disclosures related to device design, safety, and human factors testing.

Analytically, qualitative insights were triangulated with technical dossier reviews and comparative assessments of device architectures such as gas-driven versus spring-driven jet injectors and the spectrum of microarray patch modalities including dissolvable, hollow, and solid microarrays. The research also evaluated drug-specific considerations for insulin and vaccine delivery, with attention to the pharmacologic subcategories and formulation constraints that affect device selection. Supply chain analysis incorporated trade policy review, component sourcing patterns, and manufacturing footprint evaluation to assess resilience and scalability.

Throughout the methodology, findings were validated via follow-up interviews and cross-checked against regulatory submissions and clinical trial results where available. This composite approach ensures that conclusions reflect both technical realities and the practical considerations that govern adoption across varied healthcare settings.

Strategic conclusion highlighting the technical promise, implementation prerequisites, and policy-sensitive supply chain choices essential for successful needle-free adoption

Needle-free drug delivery represents a substantive shift in how medicines and vaccines can be administered, with implications that span clinical practice, patient experience, and supply chain design. Technological innovations in jet injectors and microarray patches are enabling new routes of administration and facilitating deployment in a wider range of care settings. These advances, when combined with thoughtful regulatory engagement and resilient manufacturing strategies, can mitigate traditional barriers to adoption and open pathways for broader public health impact.

However, success is contingent on aligning device capabilities with drug-specific requirements, demonstrating consistent performance across diverse populations, and articulating clear value propositions to payers and health systems. Additionally, policy dynamics such as tariffs and trade measures require deliberate supply chain planning to maintain continuity and cost predictability. Ultimately, stakeholders who integrate engineering rigor, clinical validation, and commercial pragmatism will be best positioned to convert the promise of needle-free technologies into durable improvements in patient care and system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of wearable needle-free insulin delivery devices with real-time glycemic monitoring via Bluetooth connectivity
  • 5.2. Emergence of high-pressure jet injectors for mass immunization campaigns to reduce cold chain dependency in low-resource settings
  • 5.3. Partnerships between biotech firms and device manufacturers for developing plasmid DNA vaccines administered via needle-free electroporation systems
  • 5.4. Adoption of spring-powered needle-free injectors for administering biologics in home care settings to improve patient adherence and reduce waste
  • 5.5. Regulatory approvals for mucosal needle-free nasal vaccine delivery platforms targeting respiratory pathogens and improving mucosal immunity

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Needle Free Drug Delivery Device Market, by Product Type

  • 8.1. Jet Injector
    • 8.1.1. Gas Powered
    • 8.1.2. Spring Based
  • 8.2. Microarray Patch
    • 8.2.1. Dissolvable Microarray
    • 8.2.2. Hollow Microarray
    • 8.2.3. Solid Microarray

9. Needle Free Drug Delivery Device Market, by Drug Type

  • 9.1. Insulin
    • 9.1.1. Basal Insulin
      • 9.1.1.1. Intermediate Acting Insulin
      • 9.1.1.2. Long Acting Insulin
    • 9.1.2. Bolus Insulin
      • 9.1.2.1. Rapid Acting Insulin
      • 9.1.2.2. Short Acting Insulin
  • 9.2. Vaccines
    • 9.2.1. Covid-19 Vaccine
      • 9.2.1.1. Mrna Vaccine
      • 9.2.1.2. Viral Vector Vaccine
    • 9.2.2. Influenza Vaccine
      • 9.2.2.1. H5N1 Influenza
      • 9.2.2.2. Seasonal Influenza

10. Needle Free Drug Delivery Device Market, by Administration Route

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Subcutaneous

11. Needle Free Drug Delivery Device Market, by Application

  • 11.1. Dermatology
  • 11.2. Diabetes Management
  • 11.3. Immunization
  • 11.4. Pain Management

12. Needle Free Drug Delivery Device Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Care Settings
  • 12.4. Hospitals

13. Needle Free Drug Delivery Device Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Needle Free Drug Delivery Device Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Needle Free Drug Delivery Device Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Needle Free Drug Delivery Device Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. PharmaJet, Inc.
    • 17.3.2. Antares Pharma, Inc.
    • 17.3.3. West Pharmaceutical Services, Inc.
    • 17.3.4. Nitto Denko Corporation
    • 17.3.5. Haselmeier GmbH
    • 17.3.6. Nemera S.A.
    • 17.3.7. Kindeva Drug Delivery LLC
    • 17.3.8. Vaxxas Pty Ltd
    • 17.3.9. Bioject Medical Technologies, Inc.
    • 17.3.10. Zosano Pharma Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NEEDLE FREE DRUG DELIVERY DEVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEEDLE FREE DRUG DELIVERY DEVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEEDLE FREE DRUG DELIVERY DEVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GAS POWERED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GAS POWERED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GAS POWERED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GAS POWERED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GAS POWERED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GAS POWERED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SPRING BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SPRING BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SPRING BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SPRING BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SPRING BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SPRING BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISSOLVABLE MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISSOLVABLE MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISSOLVABLE MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISSOLVABLE MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISSOLVABLE MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISSOLVABLE MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOLLOW MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOLLOW MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOLLOW MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOLLOW MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOLLOW MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOLLOW MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SOLID MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SOLID MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SOLID MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SOLID MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SOLID MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SOLID MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTERMEDIATE ACTING INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTERMEDIATE ACTING INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTERMEDIATE ACTING INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTERMEDIATE ACTING INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTERMEDIATE ACTING INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTERMEDIATE ACTING INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY LONG ACTING INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY LONG ACTING INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY LONG ACTING INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY LONG ACTING INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY LONG ACTING INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY LONG ACTING INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY RAPID ACTING INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY RAPID ACTING INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY RAPID ACTING INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY RAPID ACTING INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY RAPID ACTING INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SHORT ACTING INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SHORT ACTING INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SHORT ACTING INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SHORT ACTING INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SHORT ACTING INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SHORT ACTING INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY H5N1 INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY H5N1 INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY H5N1 INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY H5N1 INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY H5N1 INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY H5N1 INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SEASONAL INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SEASONAL INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SEASONAL INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SEASONAL INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SEASONAL INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SEASONAL INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY IMMUNIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY IMMUNIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY IMMUNIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY IMMUNIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY IMMUNIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY IMMUNIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES,